With a market capitalisation of ₹8,431 crores, the small-cap hospital operator has delivered exceptional returns of 57.41% over the past year, substantially outperforming the Sensex by 63.81 percentage points. The company's aggressive expansion strategy continues to drive top-line growth, with Q4 FY26 revenues reaching ₹341.56 crores, up 6.58% quarter-on-quarter and an impressive 47.36% year-on-year. However, margin pressures remain a key concern for investors evaluating the sustainability of this growth trajectory.
The hospital chain's financial year FY26 concluded on a strong note, with full-year revenues reaching ₹880.00 crores – a 31.30% increase from FY25 – and full-year net profit climbing to ₹130.00 crores. The company's aggressive bed capacity expansion programme has been the primary driver of this growth, though it has come at the cost of margin compression as new facilities ramp up operations.
| Quarter | Revenue (₹ Cr) | QoQ Change | YoY Change | Net Profit (₹ Cr) | QoQ Change | YoY Change | PAT Margin |
|---|---|---|---|---|---|---|---|
| Mar'26 | 341.56 | +6.58% | +47.36% | 47.52 | +4.79% | +22.73% | 13.09% |
| Dec'25 | 320.47 | +14.69% | +46.23% | 45.35 | +9.97% | +48.74% | 13.44% |
| Sep'25 | 279.42 | +8.40% | +28.31% | 41.24 | -1.90% | +33.25% | 14.76% |
| Jun'25 | 257.77 | +11.21% | — | 42.04 | +8.57% | — | 16.31% |
| Mar'25 | 231.78 | +5.76% | — | 38.72 | +26.99% | — | 16.71% |
| Dec'24 | 219.16 | +0.64% | — | 30.49 | -1.49% | — | 13.91% |
| Sep'24 | 217.77 | — | — | 30.95 | — | — | 14.21% |
Financial Performance: Growth Accelerates Amid Margin Pressures
Yatharth Hospital's Q4 FY26 financial performance reflects the dual narrative of aggressive expansion and operational challenges. Net sales for the quarter reached ₹341.56 crores, representing the highest quarterly revenue in the company's history and marking sequential growth of 6.58% from Q3 FY26's ₹320.47 crores. The year-on-year comparison is even more impressive, with revenues surging 47.36% from Q4 FY25's ₹231.78 crores, underscoring the rapid scaling of operations.
However, profitability metrics reveal a more nuanced picture. Operating profit before depreciation, interest, tax (PBDIT) excluding other income stood at ₹79.91 crores in Q4 FY26, yielding an operating margin of 23.40%. Whilst this represents the highest absolute PBDIT figure, the margin has contracted from 24.61% in Q4 FY25 and remained relatively flat compared to Q3 FY26's 23.17%. This margin compression reflects the typical trajectory of hospital chains during expansion phases, where new facilities operate at sub-optimal utilisation levels before achieving scale efficiencies.
Employee costs continued their upward trajectory, reaching ₹70.10 crores in Q4 FY26 compared to ₹63.54 crores in Q3 FY26 and ₹43.82 crores in Q4 FY25. This 59.95% year-on-year increase in employee expenses reflects both the hiring requirements for new facilities and potential wage inflation in the healthcare sector. As a percentage of revenues, employee costs stood at 20.52% in Q4 FY26, up from 18.91% in Q4 FY25, indicating some pressure on cost management.
Net profit after tax (PAT) for Q4 FY26 reached ₹47.52 crores, translating to a PAT margin of 13.09%. Whilst absolute profit figures have grown steadily, the margin compression from 16.71% in Q4 FY25 to 13.09% in Q4 FY26 represents a 362 basis point deterioration. This decline stems from a combination of factors: higher depreciation charges from new assets (₹30.00 crores in Q4 FY26 versus ₹12.87 crores in Q4 FY25), elevated interest costs during the expansion phase, and operating leverage yet to be fully realised at newer facilities.
Quality of Earnings: Strong Cash Generation
Despite margin pressures, Yatharth Hospital demonstrated strong cash flow generation in FY26, with operating cash flow of ₹149.00 crores – a significant turnaround from negative ₹3.00 crores in FY25. This robust cash generation, coupled with the company's net cash position (negative net debt-to-equity of -0.15), provides financial flexibility for continued expansion whilst maintaining balance sheet strength. The company's closing cash position stood at ₹361.00 crores at the end of FY26, up from ₹112.00 crores in FY25.
Operational Challenges: Return Ratios Under Pressure
The company's return on equity (ROE) tells an important story about the efficiency of capital deployment during this aggressive expansion phase. The latest ROE of 9.03% remains substantially below the company's five-year average of 11.44%, reflecting the typical pattern where capital-intensive expansion temporarily depresses return ratios before new assets reach optimal utilisation. It is crucial to note that higher ROE indicates better capital efficiency and profitability – a metric where Yatharth Hospital currently lags behind some peers in the hospital sector.
Return on capital employed (ROCE) presents a similar narrative. The latest ROCE of 12.32% compares unfavourably to the five-year average of 19.03%, underscoring the impact of significant capital deployment in new facilities that have yet to reach maturity. The company's sales-to-capital-employed ratio of 0.66x suggests that substantial capital is currently tied up in assets that are in the early stages of revenue generation. As these facilities mature and occupancy rates improve, both ROCE and ROE should witness gradual improvement.
The balance sheet reflects the company's transformation from a debt-laden entity to a well-capitalised organisation. Long-term debt stood at just ₹0.97 crores at the end of FY26, down dramatically from ₹75.25 crores in FY25 and ₹200.59 crores in FY23. This deleveraging was facilitated by a successful equity fundraise that bolstered shareholder funds to ₹1,605.46 crores from ₹874.32 crores in the previous year. The company's debt-to-EBITDA ratio of 0.23 and interest coverage ratio of 36.66x underscore the minimal financial risk profile.
⚠️ Key Concern: Margin Sustainability
The progressive decline in operating margins from 25.09% in Sep'24 to 23.40% in Mar'26, coupled with PAT margin compression from 16.71% to 13.09% over the same period, warrants close monitoring. Whilst expansion-related pressures are understandable, investors should track whether margins stabilise or continue deteriorating in coming quarters. The company's ability to improve occupancy rates at newer facilities and achieve operating leverage will be critical to restoring profitability ratios to historical levels.
Expansion Strategy: Aggressive Capacity Addition Drives Growth
Yatharth Hospital's growth strategy centres on rapid bed capacity expansion across tier-2 and tier-3 cities in North India. Fixed assets on the balance sheet surged to ₹597.77 crores at the end of FY26 from ₹440.47 crores in FY25, representing a 35.71% increase. This substantial capital expenditure reflects the commissioning of new facilities and expansion of existing ones. The company's cash flow statement reveals investing activities of ₹420.00 crores in FY26, primarily directed towards capacity expansion.
The hospital chain's positioning in tier-2 and tier-3 cities offers a differentiated growth opportunity compared to metro-focused competitors. These markets typically have lower competitive intensity, higher demand-supply gaps, and better unit economics once facilities reach optimal scale. However, the challenge lies in achieving adequate occupancy rates quickly enough to justify the capital deployed. The current margin pressures suggest that several facilities are still in the ramp-up phase.
Employee headcount expansion has been substantial, with total employee costs rising from ₹162.00 crores in FY25 to an estimated ₹235.00 crores in FY26 (based on quarterly run-rate). This 45% increase in personnel costs reflects both the hiring requirements for new facilities and the company's focus on maintaining quality clinical talent. As revenues scale further, employee cost as a percentage of sales should moderate, contributing to margin recovery.
| Metric | FY26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| Revenue (₹ Cr) | 880.00 | 880.00 | 670.00 | 520.00 | 400.00 |
| YoY Growth | — | +31.3% | +28.8% | +30.0% | +75.4% |
| PBDIT (₹ Cr) | — | 225.00 | 182.00 | 135.00 | 111.00 |
| PBDIT Margin | — | 25.6% | 27.2% | 26.0% | 27.8% |
| PAT (₹ Cr) | — | 130.00 | 114.00 | 65.00 | 44.00 |
| PAT Margin | — | 14.8% | 17.0% | 12.5% | 11.0% |
Industry Leadership: How Yatharth Hospital Compares to Peers
Within the hospital sector, Yatharth Hospital occupies a unique position as a rapidly scaling player focused on tier-2 and tier-3 markets. The company's valuation and operational metrics provide interesting contrasts when compared to established peers. With a market capitalisation of ₹8,431 crores, Yatharth ranks as the sixth-largest hospital chain by market value among listed peers.
The company's ROE of 11.44% (five-year average) positions it in the middle of the peer group. Rainbow Children's Hospital leads with an ROE of 17.62%, whilst Jupiter Life Line Sciences demonstrates 13.53%. However, Yatharth's ROE compares favourably to Dr Agarwal's Health Care (5.55%) and Healthcare Global (3.63%). The key question for investors is whether Yatharth can improve its ROE as new facilities mature and operating leverage improves.
| Company | P/E (TTM) | P/BV | ROE (%) | Debt/Equity | Div Yield |
|---|---|---|---|---|---|
| Yatharth Hospital | 47.04 | 4.66 | 11.44 | -0.15 | NA |
| Dr Agarwal's Health | 115.02 | 7.51 | 5.55 | 0.39 | NA |
| Rainbow Children's | 49.38 | 9.10 | 17.62 | 0.25 | 0.22% |
| Park Medi World | 50.04 | 5.94 | 0.0 | 0.00 | NA |
| Healthcare Global | 167.60 | 7.34 | 3.63 | 0.90 | NA |
| Jupiter Life Line | 44.78 | 5.73 | 13.53 | 0.03 | 0.15% |
From a valuation perspective, Yatharth's P/E ratio of 47.04x appears reasonable relative to peers. Dr Agarwal's Health Care trades at a substantial premium of 115.02x, whilst Healthcare Global commands 167.60x earnings. Rainbow Children's (49.38x), Park Medi World (50.04x), and Jupiter Life Line (44.78x) trade in a similar valuation band to Yatharth. The company's price-to-book ratio of 4.66x is the lowest among peers, suggesting relatively modest expectations embedded in the stock price compared to the sector.
Yatharth's net cash position (debt-to-equity of -0.15) represents a competitive advantage, providing financial flexibility for continued expansion without the burden of interest costs. This compares favourably to Healthcare Global's leverage ratio of 0.90 and Dr Agarwal's 0.39. Only Park Medi World and Jupiter Life Line maintain similarly conservative balance sheets among the peer group.
Valuation Analysis: Premium Justified by Growth, But Stretched
At the current market price of ₹820.10, Yatharth Hospital trades at a P/E ratio of 47.04x based on trailing twelve-month earnings. This represents a substantial premium to the broader market but a discount to the hospital sector average P/E of 62x. The company's valuation grade has oscillated between "Expensive" and "Very Expensive" over the past year, currently sitting in "Very Expensive" territory – a classification it has held since early September 2025 with brief interludes.
The company's price-to-book ratio of 4.66x reflects a premium to book value, though this appears reasonable given the asset-intensive nature of the hospital business and the relatively young age of Yatharth's facility portfolio. The enterprise value-to-EBITDA multiple of 29.29x and EV-to-EBIT of 40.20x suggest elevated expectations for future growth and margin expansion. These multiples price in successful execution of the expansion strategy and margin recovery as facilities mature.
The PEG ratio of 1.65 provides context for the growth-adjusted valuation. With five-year sales growth of 30.84% and EBIT growth of 15.55%, the company's valuation appears stretched but not egregiously so. The key consideration is whether the company can sustain its growth trajectory whilst simultaneously improving profitability metrics. Historical precedent from the hospital sector suggests that well-executed expansion strategies can justify premium valuations during the growth phase.
The stock's 52-week range of ₹484.90 to ₹889.80 illustrates the volatility inherent in small-cap growth stories. Trading just 7.83% below its 52-week high and 69.13% above its 52-week low, the current price reflects strong momentum but limited margin of safety. The recent price action – touching ₹889.80 intraday before closing at ₹820.10 on May 25, 2026 – suggests some profit-booking after the stock's 57.41% gain over the past year.
Shareholding Pattern: Promoter Stake Reduction Raises Questions
The shareholding pattern reveals a notable change in promoter holding, which declined from 61.64% in Jun'25 to 55.80% in Dec'25 – a reduction of 5.84 percentage points. This stake reduction occurred in a single quarter and has remained stable at 55.80% through Mar'26. Whilst the absolute promoter holding of 55.80% still represents strong management alignment, the reduction warrants attention from investors seeking to understand the rationale behind this dilution.
| Quarter | Promoter | Change | FII | Change | MF | Change | Insurance | Change |
|---|---|---|---|---|---|---|---|---|
| Mar'26 | 55.80% | 0.00% | 5.25% | -0.93% | 9.37% | +0.18% | 0.62% | -0.11% |
| Dec'25 | 55.80% | -5.84% | 6.18% | -0.32% | 9.19% | +2.07% | 0.73% | -0.22% |
| Sep'25 | 61.64% | 0.00% | 6.50% | +2.16% | 7.12% | -2.31% | 0.95% | -0.83% |
| Jun'25 | 61.64% | 0.00% | 4.34% | -0.11% | 9.43% | +0.01% | 1.78% | -0.04% |
| Mar'25 | 61.64% | — | 4.45% | — | 9.42% | — | 1.82% | — |
Institutional participation remains modest, with total institutional holding at 17.26%. Foreign institutional investors (FIIs) hold 5.25% as of Mar'26, down from 6.18% in the previous quarter, suggesting some profit-booking by foreign investors. Mutual fund holding stood at 9.37% in Mar'26, showing a marginal increase of 0.18% quarter-on-quarter. The presence of seven mutual funds indicates reasonable domestic institutional interest, though the absolute level of mutual fund ownership remains relatively low compared to larger-cap hospital chains.
Insurance company holdings have declined progressively from 1.82% in Mar'25 to 0.62% in Mar'26, indicating reduced interest from this typically long-term investor category. Other domestic institutional investors (DIIs) increased their stake to 2.01% in Mar'26 from 1.09% in the previous quarter, partially offsetting the decline in insurance holdings. Non-institutional shareholders – primarily retail and high-net-worth individuals – account for 26.95% of the shareholding, representing a substantial retail following for this small-cap growth story.
Stock Performance: Exceptional Returns with High Volatility
Yatharth Hospital's stock has delivered remarkable returns across multiple timeframes, substantially outperforming both the broader market and the hospital sector. Over the past year, the stock has surged 57.41% compared to the Sensex's decline of 6.40%, generating alpha of 63.81 percentage points. This outperformance extends across shorter timeframes as well, with the stock delivering 20.33% returns year-to-date against the Sensex's 10.25% decline, producing alpha of 30.58 percentage points.
| Period | Stock Return | Sensex Return | Alpha | Hospital Sector |
|---|---|---|---|---|
| 1 Day | -4.97% | +1.42% | -6.39% | — |
| 1 Week | +1.41% | +1.56% | -0.15% | — |
| 1 Month | +14.02% | -0.23% | +14.25% | — |
| 3 Months | +17.64% | -7.03% | +24.67% | — |
| 6 Months | +6.15% | -9.57% | +15.72% | — |
| YTD | +20.33% | -10.25% | +30.58% | — |
| 1 Year | +57.41% | -6.40% | +63.81% | +20.12% |
| 2 Years | +93.83% | +1.43% | +92.40% | — |
The two-year performance is even more impressive, with the stock delivering cumulative returns of 93.83% compared to the Sensex's meagre 1.43% gain. Within the hospital sector, Yatharth has outperformed substantially, with its one-year return of 57.41% exceeding the hospital sector's 20.12% return by 37.29 percentage points. This sector outperformance reflects investor enthusiasm for the company's aggressive expansion strategy and tier-2/tier-3 city focus.
However, these exceptional returns come with commensurately high volatility. The stock's beta of 1.35 indicates it is 35% more volatile than the broader market, placing it firmly in the "high beta" category. Annualised volatility of 38.16% over the past year – nearly three times the Sensex's 12.94% volatility – underscores the elevated risk profile. The risk-adjusted return of 1.50 suggests that investors have been adequately compensated for this volatility, though the "HIGH RISK HIGH RETURN" classification warrants careful position sizing.
Technical indicators present a bullish picture, with the overall trend classified as "BULLISH" since May 8, 2026. The stock trades above all major moving averages – 5-day (₹841.97), 20-day (₹819.70), 50-day (₹742.78), 100-day (₹698.55), and 200-day (₹723.89) – indicating strong momentum. However, the MACD shows a "Mildly Bearish" signal on the monthly timeframe, suggesting some caution is warranted for short-term traders.
Investment Thesis: Growth Story with Execution Risks
The investment case for Yatharth Hospital centres on three key pillars: aggressive capacity expansion in underpenetrated markets, strong balance sheet providing financial flexibility, and demonstrated ability to scale revenues rapidly. The company's focus on tier-2 and tier-3 cities in North India addresses a significant demand-supply gap in quality healthcare infrastructure, offering a differentiated growth opportunity compared to metro-focused competitors.
The proprietary Mojo Score of 65/100 places the stock in "HOLD" territory, reflecting a balanced assessment across four key parameters. Near-term drivers are rated "POSITIVE" based on the bullish technical trend and positive quarterly financial trend. Quality assessment is "AVERAGE", acknowledging the company's decent fundamentals but modest return ratios. Valuation is classified as "EXPENSIVE", reflecting the premium multiples at which the stock trades. The overall assessment is "POSITIVE", suggesting favourable momentum despite stretched valuations.
Key Strengths & Risk Factors
✅ KEY STRENGTHS
- Exceptional Revenue Growth: 47.36% YoY revenue growth in Q4 FY26, with five-year sales CAGR of 30.84% demonstrating consistent scaling ability
- Net Cash Position: Debt-to-equity of -0.15 and closing cash of ₹361.00 crores provides financial flexibility for continued expansion
- Strong Operating Cash Flow: ₹149.00 crores in FY26 versus negative ₹3.00 crores in FY25 shows improving cash generation
- Underpenetrated Markets: Focus on tier-2 and tier-3 cities offers higher growth potential with lower competitive intensity
- Minimal Interest Burden: Interest coverage ratio of 36.66x eliminates financial risk from debt servicing
- Strong Stock Momentum: 57.41% one-year return with bullish technical trend across all major timeframes
- Reasonable Peer Valuation: P/E of 47.04x below sector average of 62x, and lowest P/BV of 4.66x in peer group
⚠️ KEY CONCERNS
- Margin Compression: PAT margin declined from 16.71% in Q4 FY25 to 13.09% in Q4 FY26, a 362 bps deterioration
- Weak Return Ratios: ROE of 9.03% and ROCE of 12.32% lag sector leaders and historical averages, indicating suboptimal capital efficiency
- Promoter Stake Reduction: 5.84% decline in promoter holding from 61.64% to 55.80% in Dec'25 quarter raises questions about management confidence
- Low Institutional Holding: Total institutional ownership of just 17.26% limits liquidity and institutional support
- High Volatility: Beta of 1.35 and annualised volatility of 38.16% make this unsuitable for risk-averse investors
- Expensive Valuation: "Very Expensive" grade with EV/EBITDA of 29.29x and PEG of 1.65 leaves limited margin of safety
- Execution Risk: Aggressive expansion requires flawless execution to achieve projected occupancy and margin recovery
Outlook: What to Watch
POSITIVE CATALYSTS
- Margin Recovery: Stabilisation and improvement in operating margins as newer facilities reach optimal utilisation levels
- Occupancy Improvement: Rising bed occupancy rates at recently commissioned facilities driving operating leverage
- Return Ratio Enhancement: ROE and ROCE improvement as capital deployed in expansion starts generating adequate returns
- Market Share Gains: Continued revenue growth outpacing sector average, indicating successful market penetration in tier-2/tier-3 cities
- Cash Flow Strength: Sustained positive operating cash flow supporting organic expansion without additional equity dilution
RED FLAGS
- Further Margin Deterioration: Continued decline in PAT margins below 13% would signal execution challenges in new facilities
- Additional Promoter Selling: Further reduction in promoter stake below 55% would raise serious concerns about management commitment
- Institutional Exit: Decline in mutual fund or FII holdings indicating waning institutional confidence
- Working Capital Pressure: Deterioration in cash flow from operations or rising working capital requirements
- Technical Breakdown: Break below 200-day moving average (₹723.89) would signal trend reversal and potential for deeper correction
The Verdict: Promising Growth Story, But Wait for Better Entry
Score: 65/100
For Fresh Investors: Not recommended for fresh purchases at current levels. The "Very Expensive" valuation grade, coupled with margin compression and modest return ratios, suggests limited margin of safety. Consider accumulating on dips towards ₹725-750 levels (near 200-day MA) or await evidence of margin stabilisation in coming quarters. The high beta of 1.35 and volatility of 38.16% make this suitable only for aggressive growth investors with high risk tolerance.
For Existing Holders: Continue to hold with a trailing protective approach. The positive financial trend, strong revenue growth momentum, and bullish technical picture support maintaining positions. However, closely monitor quarterly margins and occupancy trends. Consider partial profit booking if the stock approaches ₹900-920 levels (10-12% upside from current levels) or if margins deteriorate further in Q1 FY27 results.
Fair Value Estimate: ₹750-780 (8.5% downside to 4.9% downside from current price of ₹820.10), based on 42-45x FY27 estimated earnings and assuming margin stabilisation. Current price reflects optimistic assumptions about execution success.
Note- ROCE = (EBIT - Other income)/(Capital Employed - Cash - Current Investments)
⚠️ Investment Disclaimer
This article is for educational and informational purposes only and should not be construed as financial advice. Investors should conduct their own due diligence, consider their risk tolerance and investment objectives, and consult with a qualified financial advisor before making any investment decisions. Past performance is not indicative of future results. The hospital sector involves specific operational and regulatory risks that may materially impact company performance.
